Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SNS-314 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose escalating cohorts of SNS-314 | EXPERIMENTAL | Sequential groups, starting at a dose of 30 mg/m2, will be escalated according to identification of dose limiting toxicities against various criteria. Doses escalated by doubling the dose until the first observation of clinically significant Grade 2 or greater toxicity related to SNS-314 injection. Results in dosing increments of 67%, 50%, 40%, 33%, and subsequently 25% based on modified Fibonacci schema. |
| Name | Type | Description |
|---|---|---|
| SNS-314 | DRUG | Stage 1 - Escalating doses of SNS-314 Injection on days 1, 8 and 15 Stage 2 - Same as stage 1 except SNS-314 Injection is administered at the maximum tolerated dose established in stage 1 |
Inclusion Criteria: * Advanced solid tumor and that is measurable by a scan Exclusion Criteria: * Uncontrolled or untreated central nervous system metastases * Cerebrovascular accident/transient ischemic attack up to 6 months before Cycle 1 Day 1 * Any of the following cardiac conditions: * Histo...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
SNS-314 is an investigational small molecule being studied for the treatment of advanced solid tumors. It was evaluated in a Phase 1 clinical trial in adult patients with advanced solid tumors. It is not approved for any indication and remains in clinical development.
SNS-314 targets the Aurora kinases AURKA, AURKB, and AURKC. It is an inhibitor of these enzymes. Aurora kinases regulate cell division, and inhibiting them is the intended mechanism of action for this oncology candidate.
SNS-314 is being developed by Viracta Therapeutics, Inc., which trades under the ticker VIRX. The company is the sponsor of the clinical program for this Aurora kinase inhibitor in advanced solid tumors.
SNS-314 is in Phase 1 development. It has completed one Phase 1 trial in advanced solid tumors. It is investigational and has not been approved by the FDA for any use.
SNS-314 was studied in the Phase 1 trial NCT00519662, titled Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors. The trial enrolled 32 participants in the United States and is completed. No active trials are ongoing.